Ready to Launch: ADAPT Study Looks at Intermittent Dosing of PrEP
June 7, 2011
Investigators at the HIV Prevention Trials Network (HPTN) Annual Meeting Monday received an update on a study looking to ease the pill burden on those wishing to benefit from pre-exposure prophylaxis (PrEP).
Inspired by studies of non-human primates over the past seven years at the Centers for Disease Control and Prevention, the HPTN 067 "ADAPT" study (Alternate Dosing to Augment PrEP Tablet-taking) is a behavioral study looking at how adherence can be improved by lowering the frequency and potency of each dose, while achieving "comparable" efficacy in preventing HIV infection.
The primate studies, "... Encourage us that daily doses might not be necessary, and easier dosing that is better adaptable to people may be possible," said Bob Grant, MD, of the Gladstone Institute of Virology and Immunology in San Francisco, who presented on the study.┬á The idea of adapting PrEP regimens to the patients' needs was well-received by the audience, and Grant said it was a key concept to improving adherence, "especially in terms of ┬ápeople whose lives are not defined by a disease they don't have."View Full Article
Visit Project Inform's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)